Product Description
GlaxoSmithKline was developing gsk-2890457, an oral agent for type 2 diabetes. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01725126)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Obesity
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| NCT01725126 | P2 |
Completed |
Obesity |
2013-09-12 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|